Area Sanitaria De Ferrol — Clinical Trial Site

55 Registered trials

19 Currently recruiting

Organisation

Area Sanitaria De Ferrol

Location

Ferrol, Spain

Identifier

ORG-100042488

Address

Avenida Residencia S/n, 15405, Spain

Departments

#3447: Endocrinología
#ES10004:Digestivo
3117: Cardiología
Área Sanitaria De Ferrol
Cardiology
Departamente de Gastroenterologia
Digestive
Digestive service
Endocrinología
Endocrinology
Endocrinology and metabolism
Endrocrinology
ES10004: Aparato Digestivo
ES1008; Digestivo
Gastroenterology
Gastroenterology Department
Internal medicine
Medicina Interna
n/a
NA
Nephrology
Oncología
Oncology
Respiratory Department
Servicio de Digestivo
Servicio de Digestivo - Unidad de EICI
Servicio de Endocrinologia Planta 1
Servicio de Endocrinología y Nutrición
Servicio de Medicina Interna
Unidad de Hipertensión
Urology

Clinical trials at this site (55)

Search interface

ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised

2022-500536-11-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending

2025-521590-13-00 Moderately to Severely Active Crohn’s Disease 5
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting

2025-523106-32-00 Obesity or Overweight and Type 2 Diabetes 5 2026-05-25
Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting

2023-508804-39-00 Ulcerative Colitis or Crohn’s Disease 5 2025-10-15
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe… Recruiting

2024-520209-38-00 Obesity or Overweight 5 2025-09-19
Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting

2023-503188-40-00 Active Ulcerative Colitis or Crohn’s Disease 5 2025-01-06
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's Dis… Recruiting

2023-509618-12-00 Crohn's Disease (CD) 5 2024-09-11
Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis… Recruiting

2022-502050-14-00 Crohn's disease 5 2024-06-04
AMAZE 5: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose… Recruiting

2024-520444-42-00 Overweight or obesity, and knee osteoarthritis 5 2026-04-15
AMAZE 6: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose… Recruiting

2024-520445-23-00 Overweight or obesity, and knee osteoarthritis 5 2026-04-15
A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting

2025-522046-42-00 Colonic disease 5 2026-03-24
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD Recruiting

2025-523020-50-00 Chronic Obstructive Pulmonary Disease 4 2026-03-04
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting

2024-519493-39-00 High-risk Non-muscle-invasive Bladder Cancer with Susce 5 2025-12-09
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Crohn’s Disease 5 2025-09-19
A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug… Recruiting

2023-504898-20-00 Thyroid neoplasms: ● Cohort 1: Advanced radioactive-iod 4 2024-07-30
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit… Recruiting

2023-504835-42-00 Heart Failure (Heart Failure with Reduced Ejection Frac 4 2024-02-29
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24